Indoco Remedies Quarterly Results for Trading Insights
In Mar 2026, Indoco Remedies (INDOCO) reported revenue ₹460 Cr and net profit ₹-24 Cr — revenue +19.2% YoY. For annual financials, live price and key ratios, visit INDOCO screener.
INDOCO Quarterly Results — Revenue, Profit & EPS Highlights
Indoco Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse INDOCO promoter holding to track promoter, FII and institutional holdings.
- Revenue of ₹460 Cr in Mar 2026 (-18.7% vs Jun 2026, +19.2% vs Mar 2025)
- Net Profit of ₹-24 Cr in Mar 2026 (-136.9% vs Jun 2026, +41.5% vs Mar 2025)
- EBITDA of ₹34 Cr in Mar 2026 (-75.5% vs Jun 2026)
- Operating Margin of 7.0% in Mar 2026 (-2.0pp vs Jun 2026)
- Earnings Per Share of ₹-2.57 in Mar 2026 (-136.2% vs Jun 2026)
Indoco Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
INDOCO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 460 | 566 | 473 | 386 | 433 | -18.7% | 19.2% |
| Net Profit (₹ Cr) | -24 | 65 | -9 | -41 | -36 | - | - |
| EBITDA (₹ Cr) | 34 | 139 | 30 | -5 | 10 | - | - |
| EPS (₹) | -2.57 | 7.09 | -1.00 | -4.48 | -3.94 | - | - |
| Operating Margin (%) | 7.0% | 9.0% | 6.0% | -2.0% | 2.0% | - | - |
INDOCO Share Price Trend — 1-Year Movement Across Quarterly Results
Indoco Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View INDOCO annual price range for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
INDOCO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Indoco Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores